Cosunter Obtains 1st Approval for Production of TDF for HBV Indications
On May 18, the important medicine of Fujian Cosunter Pharmaceutical Co., Ltd., “Fuganding-Tenofovir Disoproxil Fumarate Capsules (Approval No.:SFDA 2017H0005) is successfully approved.
Disclosure of Cosunter’s Environmental Influence Assessment Report for Its Synthetic Drug Technology Renovation Project
Cosunter has engaged an EIA institution to prepare the Environmental Influence Assessment Report for Cosunter’s Synthetic Drug Technology Renovation Project.
Strategic Cooperation Agreement signed by Cosunter and Sinopharm Group
Both parties hope to share all strategic resources by intercommunication on the basis of separated purchasing negotiated and relying on third-party logistics and multiple-warehouse operation for the win-win purpose.
Clinical Data Collected over Three Years from TDF-ETV Non-inferiority Control Trial by Cosunter First Released Globally at APASL Annual Meeting 2017
The 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) was held at Shanghai International Convention Center on February 15 - 19, 2017 in Shanghai, China.
Strategic Cooperation Framework Agreement Signed by Cosunter and WuXi AppTec for “the Best Plan of HBV Treatment”
Cosunter cooperated with WuXi AppTec regarding the project related to HBV treatment method independently developed by Cosunter for the purpose of “the Best Plan of HBV Treatment”. The Strategic Cooperation Framework Agreement was signed by both parties on February 9, 2017.
Cosunter’s Annual Meeting Themed “Transformation to a New Stage in 2017” Held in Fuzhou
Time flies and a busy year - 2016 has passed but an expectant new year - 2017 is saying hi to us. A new year means new target and new hope. Fujian Cosunter Pharmaceutical Co., Ltd. held its annual meeting themed “transformation to a new stage in 2017” in Fuzhou from January 22 to 23, 2017. All staff members were excited to witness and share these warm and impressive moments during the meeting.
Second Disclosure of Cosunter’s Environmental Influence Assessment for Its Synthetic Drug Technology Renovation Project
Cosunter has engaged an EIA institution to prepare the Environmental Influence Assessment Report for Cosunter’s Synthetic Drug Technology Renovation Project (simplified edition). We disclose the preliminary conclusion of this EIA for the project to the public according to the Law of the People's Republic of China on Appraising of Environment and the Temporary Methods of Public Consultation for EIA.
Cosunter's 6th Scholarship and Sponsorship Award Ceremony (SSAC 2016) Successfully Held in Ningde
Cosunter's SSAC with the theme “Cheer You on for Sailing Your Dreams” came to a successful end at Zherong No.1 High School of Fujian on August 19, 2016. Targeting the top students in the college entrance examination and poverty-stricken students from Zherong No.1 High School of Fujian and excellent students from Fujian Zherong Vocational Technical School, a total of 100 students were awarded the scholarship or sponsorship.
Cosunter Won the Title of “Fujian Enterprise of Good Creditworthiness”
We are pleased to announce that Fujian Cosunter Pharmaceutical Co., Ltd. among other 17 pharmaceutical companies, has been awarded the title of “2014-2015 Fujian Enterprise of Good Creditworthiness” by the Administration for Industry & Commerce of Fujian. In these companies, three are provincial companies, three in Fuzhou, two in Ningde, three in Xiamen, three in Zhangzhou, two in Nanping and two in Longyan.
Cosunter Obtains Partial Results in Hepatitis C Treatment
Yesterday, Fujian Cosunter Pharmaceutical Co., Ltd. (hereinafter referred to as “the Company”) received the Clinical Trial Permission signed and issued by the China Food and Drug Administration for Sofosbuvir Tablets.